(Q37622253)

21 August 2017

1 reference

title

Update on emerging drugs for cancer cachexia (English)

1 reference

21 August 2017

2

1 reference

21 August 2017

Kate T Murphy

1

0 references

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Emerging Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

619-632

1 reference

Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Assessment and management of cancer-related fatigue in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

ABC of palliative care. Anorexia, cachexia, and nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Cancer cachexia and fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Prevention and treatment of cancer cachexia: new insights into an old problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Melanocortin interventions in cachexia: how soon from bench to bedside?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Insulin resistance in cancer patients is associated with enhanced tumor necrosis factor-alpha expression in skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Mechanisms of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Induction of muscle protein degradation by a tumour factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

IKKbeta/NF-kappaB activation causes severe muscle wasting in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Muscle myostatin signalling is enhanced in experimental cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Myostatin inhibits myoblast differentiation by down-regulating MyoD expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Evidence for activation of the renin-angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Mechanism of induction of muscle protein degradation by angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Emerging drugs for cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Estimation of Cachexia among Cancer Patients Based on Four Definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Growth hormone secretagogue receptors in rat and human gastrointestinal tract and the effects of ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Ghrelin enhances appetite and increases food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

The cannabinoid system and cytokine network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Effects of marihuana on the solution of anagrams, memory and appetite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Medicinal applications of delta-9-tetrahydrocannabinol and marijuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Recent clinical experience with dronabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Thalidomide attenuates tumor growth and preserves fast-twitch skeletal muscle fibers in cholangiocarcinoma rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Thalidomide in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

New drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Update on emerging drugs for sarcopenia - age-related muscle wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Drug increases lean tissue mass in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Myostatin antisense RNA-mediated muscle growth in normal and cancer cachexia mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

The renin-angiotensin system and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Olmesartan ameliorates insulin sensitivity by modulating tumor necrosis factor-alpha and cyclic AMP in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Potential deployment of angiotensin I converting enzyme inhibitors and of angiotensin II type 1 and type 2 receptor blockers in cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903369351

10.1517/14728210903369351

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference